In last trading session, Prelude Therapeutics Inc (NASDAQ:PRLD) saw 0.54 million shares changing hands with its beta currently measuring 1.56. Company’s recent per share price level of $1.19 trading at -$0.08 or -6.30% at ring of the bell on the day assigns it a market valuation of $65.48M. That closing price of PRLD’s stock is at a discount of -471.43% from its 52-week high price of $6.80 and is indicating a premium of 7.56% from its 52-week low price of $1.10. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.44 million shares which gives us an average trading volume of 330.99K if we extend that period to 3-months.

For Prelude Therapeutics Inc (PRLD), analysts’ consensus is at an average recommendation of Sell while assigning it a mean rating of 2.60. Splitting up the data highlights that, out of 2 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.48 in the current quarter.

Prelude Therapeutics Inc (NASDAQ:PRLD) trade information

Upright in the red during last session for losing -6.30%, in the last five days PRLD remained trading in the red while hitting it’s week-highest on Thursday, 11/07/24 when the stock touched $1.19 price level, adding 12.5% to its value on the day. Prelude Therapeutics Inc’s shares saw a change of -72.13% in year-to-date performance and have moved -4.03% in past 5-day. Prelude Therapeutics Inc (NASDAQ:PRLD) showed a performance of -38.66% in past 30-days. Number of shares sold short was 2.49 million shares which calculate 8.15 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 80.17% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -152.1% in reaching the projected high whereas dropping to the targeted low would mean a loss of -152.1% for stock’s current value.

Prelude Therapeutics Inc (PRLD) estimates and forecasts

Statistics highlight that Prelude Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -68.10% of value to its shares in past 6 months, showing an annual growth rate of 8.42% while that of industry is 18.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -43.14% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 10.79% while estimates for its earnings growth in next 5 years are of 30.10%.

Prelude Therapeutics Inc (NASDAQ:PRLD)’s Major holders

Insiders are in possession of 9.06% of company’s total shares while institution are holding 94.53 percent of that, with stock having share float percentage of 103.95%. Investors also watch the number of corporate investors in a company very closely, which is 94.53% institutions for Prelude Therapeutics Inc that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at PRLD for having 10.91 million shares of worth $41.56 million. And as of 2024-06-30, it was holding 14.4043 of the company’s outstanding shares.

The second largest institutional holder is BAKER BROS. ADVISORS LP, which was holding about 10.12 million shares on 2024-06-30. The number of shares represents firm’s hold over 13.3673 of outstanding shares, having a total worth of $38.57 million.